Liquidia Corporation
LQDA
Rang in Aktien
#4437
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Aktienkurs
$38.75
Zuletzt synchronisiert: 2026-10-21
Marktkapitalisierung
$3.47B
Veränderung (1 Tag)
6.60%
Veränderung (1 Jahr)
73.46%
Land
US
Handel Liquidia Corporation (LQDA)
Kategorie
Healthcare
Kursverlauf für Liquidia Corporation (LQDA)
Höchster Schlusskurs: $30.60 am 2026-10-01
Niedrigster Schlusskurs: $11.01 am 2018-07-01
Niedrigster Schlusskurs: $11.01 am 2018-07-01
Kursverlauf der Aktie von Liquidia Corporation von 2018 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | 42.98% |
| 2025 | 204.28% |
| 2024 | 26.82% |
| 2023 | 47.93% |
| 2022 | 37.03% |
| 2021 | 48.32% |
| 2020 | -24.23% |
| 2019 | -82.68% |
| 2018 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $62.20 | 68.82% |
US
|
|
| $46.29 | 37.83% |
SE
|
|
| $171.04 | 23.67% |
FR
|
|
| $116.39 | 58.03% |
US
|
|
| $59.46 | -0.57% |
IT
|
